Sign Up to like & get
recommendations!
0
Published in 2021 at "Scientific reports"
DOI: 10.1038/s41598-021-84836-z
Abstract: We compared the efficacy, safety, and acceptability of lurasidone at different doses to establish the dose-response relationships of lurasidone therapeutic and adverse effects in acute schizophrenia. Included trials were 4- to 16-week, fixed-dose, randomized controlled…
read more here.
Keywords:
dose response;
acute schizophrenia;
lurasidone;
day ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Pharmacopsychiatry"
DOI: 10.1055/a-1096-1266
Abstract: INTRODUCTION The use of the blonanserin patch (BLO-P) for schizophrenia treatment was approved in Japan in 2019. This systematic review of trials in Japan assessed the efficacy and safety profile of BLO-P compared with other…
read more here.
Keywords:
acute schizophrenia;
systematic review;
trials japan;
placebo ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Schizophrenia bulletin"
DOI: 10.1093/schbul/sbaa063
Abstract: Little is known regarding optimal antipsychotic doses in the acute phase of schizophrenia. The aim of the present study was to employ the concept of minimum effective dose (MED) in examining efficacy and tolerability within…
read more here.
Keywords:
schizophrenia;
acute schizophrenia;
meta analysis;
fold med ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Neuropsychiatric Disease and Treatment"
DOI: 10.2147/ndt.s169619
Abstract: Objectives Interactions between neuropeptides and psychiatric disorders have been investigated for many years. The aim of this study was to evaluate oxytocin (OXT), arginine-vasopressin (AVP), and atrial natriuretic peptide (ANP) and assess their interactions with…
read more here.
Keywords:
atrial natriuretic;
acute schizophrenia;
patients acute;
natriuretic peptide ... See more keywords